While the FDA has flip-flopped on whether to review Moderna’s combination influenza and COVID-19 vaccine, it’s full speed ...

DelveInsight's Nanomedicine Market Insights report provides the current and forecast market analysis, individual leading nanomedicine companies' market shares, challenges, nanomedicine market drivers, ...

The nanomedicine market is largely propelled by the increasing demand for precise and more effective treatments, especially for cancer, cardiovascular conditions, and other chronic diseases ...

This 21st-century centre of cutting-edge science is also a medieval site of celestial auguries, of miracle cures performed and witnessed ...

The February 2026 meeting of the EMA's Committee for Medicinal Products for Human Use (CHMP) resulted in recommendations for twelve new medicines.¹ These outcomes, which included recommendations for ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended 6 novel medicines for approval at its February 2026 meeting. These now have to be approved by the European Commission ...

Maintaining good oral health helps to prevent dental infections. If you develop pain or swelling in your mouth, call a ...

By Puyaan Singh March 4 (Reuters) - Moderna shares rose 9% on Wednesday after it settled a long-running legal battle over the ...

The Cambridge-based drug maker said the deal settles "all worldwide" litigation related to certain drugs and it won't have to pay royalties to other companies.

By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

Bernstein analyst Courtney Breen said, however, if the payment does become necessary, it could reduce the company's cash reserves to as low as $3.2 billion by 2026. Moderna expects its reserves to be ...